Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.51 |
| ▸ | F2 | P00734 | 7/20 | 0.51 |
| ▸ | KLK1 | P06870 | 2/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4879535 | 0.89 | F10 (0.53) | F10F2KLK1PLAT | |
| SCHEMBL3958973 | 0.85 | F10 (0.68) | F10F2KLK1PLAT | |
| SCHEMBL4885413 | 0.84 | F10 (0.66) | F10F2KLK1PLAT | |
| SCHEMBL3967863 | 0.83 | F10 (0.66) | F10F2KLK1 | |
| SCHEMBL3964110 | 0.82 | F10 (0.68) | F10F2KLK1 | |
| SCHEMBL3969887 | 0.82 | F10 (0.55) | F10F2KLK1 | |
| SCHEMBL3962467 | 0.81 | F10 (0.55) | F10F2KLK1 | |
| SCHEMBL1380763 | 0.80 | F10 (0.80) | F10F2KLK1 | |
| SCHEMBL3962680 | 0.80 | F10 (0.65) | F10F2KLK1 | |
| SCHEMBL1378273 | 0.80 | F10 (0.65) | F10F2KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636226-B1 | Azaindole derivatives as Factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-10-15 | — | — | EP | claimed |
| US-7317027-B2 | 1-substituted 2-carboxamide derivatives of fused ring pyrroles, especially pyrrolo[2,3-b]pyridines and pyrrolo[3,2-b]pyridines, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | claimed |
| EP-1636226-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | claimed |
| US-20050009828-A1 | Azaindole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND (DE) | 2005-01-13 | — | — | US | claimed |
| WO-2004101563-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| EP-1479680-A1 | Azaindole derivatives as Factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| EP-1636226-B1 | Azaindole derivatives as Factor Xa inhibitors | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-10-15 | — | — | EP | disclosed |
| US-20080280946-A1 | Azaindole-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-7317027-B2 | 1-substituted 2-carboxamide derivatives of fused ring pyrroles, especially pyrrolo[2,3-b]pyridines and pyrrolo[3,2-b]pyridines, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| EP-1636226-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009828-A1 | Azaindole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101563-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479680-A1 | Azaindole derivatives as Factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009828-A1 | Azaindole-derivatives as factor Xa inhibitors | F12, F5, F11 | F10 11/4885F2 8/4885KLK1 584/4885 |
| US-20080280946-A1 | Azaindole-Derivatives As Factor Xa Inhibitors | F12, F5, F11 | F10 12/4885F2 8/4885KLK1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.